ALLIANCE UPDATE

Companies	Agreement
Athena Neurosciences & Eli Lilly	Athena will exclusively market Lilly's Permax (pergolide mesylate), which treats Parkinson's disease.
Athena Neurosciences & Innogenetics	The firms will develop tau-based assays to test for Alzheimer's disease. Tau is a protein involved in neurofibrillary tangles, one of the key pathologies found in Alzheimer's.
Bio-Technology General & Sandoz	Bio-Technology General will supply Sandoz with the enzyme aeromonas aminopeptidase, which Sandoz uses to process such pharmaceutical proteins as interleukins.
Cambridge Biotech & American Cyanamid	American Cyanamid has licensed Cambridge Biotech's Stimulon QS-21 adjuvant to use in vaccines to treat or prevent certain viral and bacterial infections.
Cambridge Biotech & Univax Biologics	Univax has licensed Cambridge Biotech's Stimulon QS-21 adjuvant to produce polyclonal antibodies for use against such infectious diseases as sepsis and cystic fibrosis.
Cangene & Medi-Ject	Cangene will receive global marketing rights to Medi-Ject's needle-free drug-delivery system.
Gensia Pharmaceuticals & Upjohn	The firms will manufacture and market multisource pharmaceuticals in the U.S. for oncology and related diseases. These products—which include etoposide, cisplatin, doxorubicin, carboplatin, flurouracil, and cytarabine—are already marketed by an Upjohn subsidiary, Delta West, in Australia and Southeast Asia.
Genta & InSite Vision	To treat ophthalmic diseases, the firms will test Genta's Anticodon oligonucleotide compounds in InSite's novel drug-delivery systems.
Genta & CV Therapeutics	The firms will collaborate with Stanford University's Victor Dzau to develop Anticodon oligonucleotide drugs to prevent and treat restenosis. Dzau is recognized for his work with restenosis.
Genzyme & Omnia Res	Genzyme's diagnostic division has purchased Omnia, already the sole distributor of Genzyme research products in Italy.
Kabi Pharmacia & Arris Pharmaceutical	In a three-year alliance, Kabi will make an equity investment in Arris and fund research in exchange for worldwide marketing and manufacturing rights for resulting synthetic cytokine mimetics.
MedImmune & Boston International	Boston International will distribute CytoGram, a polyclonal antibody, in Eastern Europe and the former U.S.S.R.
Promega & Hoffmann-La Roche	Promega has filed papers in U.S. District Court in New Jersey charging that Roche's patent for taq DNA polymerase, U.S. No. 4,889,818, used in PCR is invalid. Promega argues that the taq enzyme is a natural product from a natural organism and has not been created by genetic engineering.
Protein Design Labs & Sandoz	Protein Design Labs has acquired four human monoclonal antibodies from Sandoz. The antibodies target cytomegalovirus, hepatitis B virus, herpes simplex virus, and varicella zoster virus. Sandoz will receive \$5 million up front and, potentially, \$5 million more in milestone payments.
Quidel & Epitope	The two will jointly develop fertility diagnostic tests that use oral samples. The collaboration will pair Epitope's proprietary oral-specimen collection technology with Quidel's one-step test technology.
Ribozyme Pharmaceuticals & Park-Davis	The firms will jointly develop therapeutics based on ribozyme technology, focusing initially on osteoarthritis.
Sphinx Pharmaceuticals & ICAgen	The two have formed a joint venture to develop compounds that can be delivered across ion channels. ICAgen has proprietary ion-channel assays, and Sphinx has a large library of compounds.
Systemix & Sandoz	The firms will form a 50/50 joint venture to develop somatic gene therapies to combat HIV infection. Hematopoietic stem cells will be used as a vehicle in these gene therapies.
Vertex Pharmaceuticals & Kissei	The two will develop orally active drugs to treat HIV infection and AIDS. Vertex, with financial support from Kissei, will design compounds that target HIV protease.
Xenova & Suntory	The two will use Xenova's microbial drug-discovery technology to develop compounds targeting several immune/inflammatory diseases, particularly rheumatoid arthritis. Suntory will make a \$3 million equity investment in Xenova and will potentially pay more than \$12 million in payments.

Agbiotech

Calgene & Monsanto	The companies have resolved potential patent conflicts by agreeing to several cross-licensing arrangements. They exchanged rights to each other's patents and patents pending in areas of plant transformation, ethylene repression, <i>Bacillus thuringiensis</i> insect resistance in cotton, certain genetically engineered plants, antisense RNA technology, and CaMV promoters.
--------------------	--

—Mark Goodstein